Biome Australia Locks in Exclusive Probiotic Supply Deal Through 2028

By Josua Ferreira -

Biome Australia locks in Probiotical supply certainty through to 2028

Biome Australia (ASX: BIO) has executed a two-year extension to its exclusive supply agreement with Probiotical SpA, replacing an agreement that was due to expire in June 2026. The extended agreement runs through 2028 on existing commercial terms, removing near-term supply uncertainty as the company scales internationally.

Probiotical has been a strain partner of Biome since the company’s incorporation in 2018, making this one of its longest-standing supply chain relationships. The extension reflects both parties’ commitment to continuing that arrangement as Biome expands its international footprint.

What this means for Biome’s growth runway

Extension terms at a glance

The key terms of the executed extension are as follows:

  • Duration: Two-year extension
  • Expiry: Through 2028
  • Terms: Existing commercial terms (no renegotiation)
  • Relationship commencement: 2018 (since incorporation)
  • Markets covered by Biome’s international footprint: Australia, Canada, the United Kingdom, Ireland and New Zealand

The extension removes near-term supply uncertainty and provides operational runway as Biome continues scaling across these markets.

Blair Vega Norfolk’s take

Blair Vega Norfolk, Founder and Managing Director, Biome Australia

“Probiotical has been one of our most important strategic partners since the Company was founded. This two-year extension on existing terms gives both businesses the certainty to continue executing as Biome scales internationally, and we look forward to continuing to develop the partnership alongside the ongoing investment we are making in Australian manufacturing capability.”

Understanding exclusive supply agreements in life sciences — why they matter for investors

An exclusive supply agreement differs from a standard supply contract in one important respect: it prevents the supplier from providing the same inputs to competing buyers. For a company like Biome, which relies on specific validated probiotic strains, exclusivity means competitors cannot source identical strains from Probiotical, preserving a degree of product differentiation that would otherwise be difficult to protect.

For investors, supply chain agreements of this nature carry strategic weight beyond simple logistics. Four reasons why they matter for health companies include:

  1. Strain consistency: The same validated strains are used across all markets, supporting product uniformity.
  2. Supply security: Competitors cannot access the same partner inputs, protecting Biome’s formulation advantage.
  3. Regulatory continuity: Consistent raw material sourcing supports product registrations across multiple jurisdictions.
  4. Relationship depth: Long-term partners are more likely to co-invest in product development alongside the company’s growth.

Australian onshoring and the road ahead

Running in parallel to the Probiotical extension is Biome’s Australian manufacturing onshoring program, a Biome-led initiative that is currently underway. The company has not disclosed specific milestones or completion targets at this stage, but has confirmed that a further update on Australian manufacturing is expected within calendar 2026.

The two strategic threads are complementary. The Probiotical extension secures near-term supply continuity while the onshoring program works to build longer-term domestic manufacturing capability. Investors should watch for the Australian manufacturing update within calendar 2026 as the next material milestone on this front.

Further updates and a video presentation of this announcement are available via Biome’s investor hub at investorhub.biomeaustralia.com.

Don’t Miss the Next Consumer Healthcare Winner on ASX

Big News Blast delivers FREE breaking ASX news straight to your inbox within minutes of release, complete with in-depth analysis already done for you. Over 20,000+ subscribers stay ahead of the market with real-time alerts the moment announcements drop. Click the “Free Alerts” button at StockWire X to get started today.


Frequently Asked Questions

What is an exclusive supply agreement and why does it matter for Biome Australia investors?

An exclusive supply agreement prevents the supplier from providing the same inputs to competing buyers, meaning Biome's competitors cannot source identical validated probiotic strains from Probiotical SpA, protecting Biome's product differentiation and formulation advantage.

How long has Biome Australia had a supply relationship with Probiotical SpA?

Probiotical SpA has been a strain partner of Biome Australia since the company's incorporation in 2018, making it one of Biome's longest-standing supply chain relationships, now extended through to 2028.

What markets does Biome Australia currently operate in?

Biome Australia currently operates across five markets: Australia, Canada, the United Kingdom, Ireland, and New Zealand, with the Probiotical supply extension supporting ongoing scaling across all of these regions.

When is Biome Australia's next major supply chain milestone expected?

Biome Australia has confirmed that a further update on its Australian manufacturing onshoring program is expected within calendar 2026, representing the next material milestone for investors monitoring the company's domestic manufacturing capability.

Were the terms of the Probiotical supply extension renegotiated?

No — the two-year extension to 2028 was executed on existing commercial terms, meaning Biome Australia retained the same pricing and conditions from the prior agreement without renegotiation.

Josua Ferreira
By Josua Ferreira
Partnership Director
Josua Ferreira holds a Bachelor of Commerce in Marketing and Advertising and brings a background in publication, business development, and ASX market storytelling. He has worked with listed companies across the resource sector and broader market, combining sharp commercial instincts with a genuine commitment to keeping investors informed.
Learn More
Companies Mentioned in Article

Breaking ASX Alerts Direct to Your Inbox

Join +20,000 subscribers receiving alerts.

Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.

About the Publisher